NCT03077217

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Shanghai Changzheng Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Several studies have been showed that rifaximin can improve cognitive functions, driving simulator performance and health-related quality of life in patients with minimal hepatic encephalopathy. The aim of this prospective randomized open controlled study was to evaluate the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic encephalopathy.

Conditions

• Covert Hepatic Encephalopathy

Interventions

Type	Name	Description
DRUG	Rifaximin	The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy

Timeline

• Start date: 2017-05-01
• Primary completion: 2020-05-31
• Completion: 2020-05-31
• First posted: 2017-03-10
• Last updated: 2021-07-01

Locations

1 site across 1 country: China